Table 1.
Effects of PACAP on additional 5CSRTT metrics
| Metri c |
Correct Latency (sec)a |
Time to Complete (sec)b |
Reward Latency (sec)b |
Premature Responses (no.) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose PACA P (μg) |
0. 0 |
0.2 5 |
0. 0 |
0.2 5 |
0. 5 |
1. 0 |
0. 5 |
1. 0 |
0. 0 |
0.2 5 |
0. 5 |
1. 0 |
0. 0 |
0.2 5 |
0. 5 |
1. 0 |
| VEH | 0.77 ±0.04 | 0.92 ±0.04 | 12.50 ±2.9 | 8.8 ±1.6 | 12.83 ±4.3 | 14.67 ±14.8 | 0.83 ±0.08 | 0.84 ±0.08 | 1.56 ±0.08 | 2.07 ±0.53 | 1.68 ±0.16 | 1.52 ±0.11 | 12.50 ±2.9 | 8.8 ±1.6 | 12.83 ±4.3 | 14.67 ±14.8 |
| PACAP | 0.803 ±0.03 | 1.21 ±0.06 | 15.33 ±4.97 | 7.0 ±0.6 | 3.83 ±1.5 | 2.33 ±1.1 | 1.17 ±0.34 | 0.498 ±0.23 | 1.56 ±0.09 | 1.67 ±0.19 | 1.56 ±0.34 | 0.65 ±0.29 | 15.33 ±4.97 | 7.0 ±0.6 | 3.83 ±1.5 | 2.33 ±1.1 |
| PD1 | 0.99 ±0.15 | 1.13 ±0.11 | 23.5 ±10.1 | 11.0 ±3.3 | 8.17 ±1.9 | 6.5 ±1.5 | 1.16 ±0.14 | 0.83 ±0.2 | 1.65 ±0.1 | 1.84 ±0.21 | 1.79 ±0.16 | 1.51 ±0.37 | 23.5 ±10.1 | 11.0 ±3.3 | 8.17 ±1.9 | 6.5 ±1.5 |
| PD2 | 0.79 ±0.07 | 1.05 ±0.07 | 11.0±4.4 | 10.8 ±2.8 | 9.33 ±2.4 | 9.83 ±4.9 | 0.91 ±0.06 | 0.82 ±0.09 | 1.63 ±0.08 | 1.64 ±0.16 | 2.01 ±0.38 | 1.66 ±0.2 | 11.0 ±4.4 | 10.8 ±2.8 | 9.33 ±2.4 | 9.83 ±4.9 |
| PD7 | 0.95 ±0.08 | 0.89 ±0.08 | 7.33 ±3.1 | 11.6 ±3.3 | 11.5 ±3.8 | 11.0 ±2.7 | 0.79 ±0.03 | 0.91 ±0.11 | 1.60 ±0.08 | 1.67 ±0.22 | 1.57 ±0.12 | 1.58 ±0.09 | 7.33 ±3.1 | 11.6 ±3.3 | 11.5 ±3.8 | 11.0 ±2.7 |
| Statist ics (main effect s) | Dose: F(3,19)=4.486, P<0.05 Day: F(4,76)=1.03, P=0.399, n.s. |
Dose: F(3,19)=0.316, P=0.81, n.s. Day: F(4,76)=3.529, P<0.05 |
Dose: F(3,19)=1.339, P=0.29, n.s. Day: F(4,76)=2.68, P<0.05 |
Dose: F(3,19)=0.96, P=0.43, n.s. Day: F(4,76)=1.41, P=0.24, n.s. |
||||||||||||
a
Main effects of dose. No main effects of day or interactions.
b
Main effects of day (VEH, PACAP, PD 1, PD2, PD3). No main effects of dose or interactions. Values represent mean ± SEM. PD=post treatment day. n.s. = not significant.